Tags: Diagnostics Accelerator
- addf access
- aducanumab
- agenebio
- alzecure foundation
- amylyx
- amyotrophic lateral sclerosis
- amyvid™
- apoe
- asceneuron
- axxam
- batten disease
- benefit
- beta-amyloid
- bill gates
- biogen
- biomarkers
- birax
- blog
- caregiving
- cerebrospinal fluid csf
- chronic traumatic encephalopathy cte
- clinical trials
- cognitive vitality
- cohbar
- combination therapy
- comparative effectiveness
- concussions
- conference
- connoisseur's dinner
- cypralis
- diagnostics accelerator
- drug discovery
- early-onset alzheimer's
- epigenetics
- fall luncheon
- frontotemporal dementia
- genetics
- giving tuesday
- gliacure
- great ladies luncheon
- harrington discovery institute
- hope on the horizon
- inflammation
- klogene therapeutics
- lewy body dementia
- ltd.
- m3 biotechnology
- medicare
- melvin r. goodes prize
- memories matter
- mild cognitive impairment
- misfolded proteins
- mitochondria & metabolic function
- mri
- multiple scleroris
- neuroimaging
- neurolucent
- neuroprotection
- neurotherapia
- neurotransmitters
- new staff
- new trustees
- nyc marathon
- oryzon genomics
- partnership
- pet scan
- pharmatrophix
- policy
- prevention
- prion disease
- proteostasis
- psychogenics
- repurposing
- rexceptor
- rodin therapeutics
- runners for alzheimer's research
- supplements
- tau
- tdp-43
- tetra discovery partners
- traumatic brain injury
- vascular
- vascular dementia
- venture philanthropy
- vivreon biosciences
- world alzheimer's day
- year in review
announcements
November 22, 2019
Major Research Funding for Blood Test to Accelerate Clinical Trials for New Frontotemporal Degenerat
The Bluefield Project to Cure FTD Receives $1.2 Million Award from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator
announcements
October 17, 2019
Alzheimer’s Drug Discovery Foundation Partners with Shionogi and Janssen Pharmaceuticals for its Dia
The Alzheimer’s Drug Discovery Foundation (ADDF) announced a partnership with Shionogi & Co., Ltd. and Janssen Pharmaceuticals, Inc. as part of its Diagnostics Accelerator, an initiative that aims to fast-track the development of novel biomarkers for the early detection of Alzheimer's disease and related dementias.
announcements
July 15, 2019
ADDF Clinical Trials Report Shows Notable Shift from Amyloid Approaches
The Alzheimer's Drug Discovery Foundation (ADDF) released a new clinical trial analysis report that shows researchers are now developing drugs for various targets associated with aging biology – moving beyond traditional amyloid and tau approaches.
announcements
May 31, 2019
Thirteenth Connoisseur’s Dinner Recognizes Core Funders of Its Diagnostics Accelerator
The ADDF celebrated the one-year anniversary of the Diagnostics Accelerator initiative and its core funders at the ADDF's annual gala.
announcements
May 30, 2019
Alzheimer’s Drug Discovery Foundation Announces the First Diagnostics Accelerator Award Recipients
The first four awards from the first request for proposals total up to approximately $3.5 million.
announcements
April 2, 2019
The ADDF Announces New Research Initiative to Advance Digital Tools for Detection for Alzheimer’s
The ADDF's Diagnostics Accelerator is seeking to fund the development of digital tools to capture quantifiable biomarkers.
announcements
March 21, 2019
ADDF Statement on Biogen and Eisai Discontinuing Trials of Aducanumab
Pharmaceuticals company Biogen and its partner Eisai announced that they will cease clinical trials for aducanumab after it was indicated the trials were unlikely to succeed.
blog
January 14, 2019
Top 5 Advances in 2018
In 2018 we have seen increased investments in Alzheimer's biomarkers and increased interest in prevention.
announcements
January 3, 2019
The ADDF’s Diagnostics Accelerator Initiative Expands Its Focus on Frontotemporal Degeneration
The ADDF's Diagnostics Accelerator is matching a $2.5 million research investment from The Association for Frontotemporal Degeneration to invest in biomarkers for frontotemporal dementia.
blog
September 24, 2018
Two Decades of Research: The ADDF’s 19th International Conference on Alzheimer’s Drug Discovery
Researchers shared updates on their approaches to developing Alzheimer's treatments at our annual conference.
announcements
September 21, 2018
19th International Conference on Alzheimer’s Drug Discovery Highlights Multiple Approaches
The conference, organized by the Alzheimer's Drug Discovery Foundation, focused on gene therapy and alternative modalities for neurodegenerative diseases, progress in developing novel drugs, as well as the need for new biomarkers.
announcements
July 17, 2018
New Coalition of Philanthropists Including Bill Gates, Leonard Lauder Commit More Than $30 Million
Bill Gates and Leonard Lauder have announced Diagnostics Accelerator, an initiative to develop new biomarkers for early detection for Alzheimer's.
Alzheimer's Drug Discovery Foundation
A GuideStar-Rated Charity
New York, NY 10019
info@alzdiscovery.org
212.901.8000
© Copyright 2024. The Alzheimer's Drug Discovery Foundation, a not-for-profit, section 501 (c)(3).